Globus Medical Guidance Cut Disappointing, RBC Says

MT Newswires Live11-07

Globus Medical (GMED) delivered a disappointing cut in top-line guide amid delayed product launches and slower Nevro recovery, RBC Capital Markets said in a report Thursday.

The note said the shortfall was execution-driven and timing-related rather than structural.

The company called out US Spine slowdown to delayed product launches and softer competitive recruiting rather than purely market weakness, the report said.

"Looking ahead, several new products are creating a stacked launch cadence that we believe positions GMED for a meaningful acceleration in 2027+," the note said.

The report said Globus is showing the quality of its underlying margin and cash flow profile with a reiteration of its EPS guide, reflecting eight straight quarters of sequential margin expansion.

RBC kept its outperform rating and a price target of $85.

Price: 71.81, Change: -9.63, Percent Change: -11.83

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment